The Transcriptomics market is expected to register a CAGR of 5.57% over the forecast period.
The COVID-19 has had a both positive as well as a negative impact on life science as well as the pharmaceutical industry globally. Certain market segments have been more severely affected due to the decrease in the demand for reagents, consumables, and instruments as well as due to supply chain disruptions and trade restrictions. In June 2020, NanoString Technologies, Inc. launched new solutions to study the immune response in COVID-19 disease research. The company launched the nCounter Host Response Gene Expression Panel and the COVID-19 Panel Plus spike-in to provide a comprehensive analysis of the viral infection and immune response. Thus, the current global pandemic has created considerable opportunities for the market players operating in the space.
Transcriptomics is the study of the entire set of RNA transcripts produced by the genome of any organism. Increase in advancements in the field of transcriptomics such as extensive use of RNA-sequencing and rise in application of transcriptomics, which includes drug discovery is expected to drive the growth of the transcriptomics market. In addition, rise in funding and grants by various private and government organizations have further stimulated the growth of the Transcriptomics Market.
Moreover, key market players are focused on expanding their transcriptomics footprints by entering into strategic partnerships and collaborations with other players. Moreover, the companies are undertaking strategies to expand their customer base across the globe. For instance, in February 2020, Dovetail Genomics announced the global availability of its Dovetail HiChIP and Micro-C Kits.
In Februry 2020, Caris Life Sciences launched of its newest addition to its comprehensive genomic profiling offering, MI Transcriptome, which enables Whole Transcriptome Sequencing (WTS). MI Transcriptome uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patients’ tumors and builds upon Caris’ offering of the most comprehensive tumor profiling approach, which assesses DNA, RNA and proteins to ensure patients receive the right therapies. Such product launches will work in the favour of the market growth.
However, certain drawbacks of RNA sequencing and lack of skilled professionals are expected to restrain the market growth.
Key Market Trends
Application of Transcriptomics in Diagnostics and Disease Profiling is expected to Grow in the forecast period
Transcriptomics has a variety of applications in diagnostics and disease analysis. Transcriptome analyses have been extensively used to understand the heterogeneity of tumors, classifying tumors into molecular subtypes and establishing signatures that predict response to therapy and patient outcomes. Massively-parallel single-cell RNA sequence analysis has emerged as a powerful method to understand the heterogeneity and to study cancer’s rare cell populations, through unsupervised sampling and modeling of transcriptional states in single cells.
The global spread of COVID-19 urgently demands a more comprehensive molecular understanding of the disease pathophysiology. And while an effective vaccine candidate is still elusive, therapeutic management of COVID-19 patients is pivotal in mitigating the clinical burden, as well as decreasing mortality rates. The research article published "Use of whole blood transcriptomes may improve COVID-19 diagnosis and treatment" in 2020, reported the first evidence for the use of whole blood transcriptomics to distinguish coronavirus disease (COVID-19) from other infections, and also to monitor and potentially predict disease outcomes. Thus, rising use of transcriptomics in the field of COVID-19 is likely have profiund impact on the market studied.
In recent years, transcriptomics has shifted from strictly research applications to diagnostics and disease applications. Transcriptomics are major tools for accelerating disease diagnostics processes. With the rapidly increasing global burden of chronic diseases such as cancer and diabetes, there is a need for advanced technologies for diseases and diagnostics. For instance, as per the report published by GLOBOCAN 2020, there were around 19.2 million new cases and 9.95 million deaths of cancer were reported across the globe. This rapidly increasing patient pool is likely to positively influencing segmental growth.
Various market players operating in the transcriptomics market are constantly focusing on developing and introducing novel instruments and techniques in the arena of diseases and diagnostics. For instance, in October 2019, Ambry Genetics (Ambry) launched the transcriptomic test namely +RNAinsight. This test enables clinicians for the first time ever to conduct both DNA and RNA genetic testing at the same time. Hence, owing to the afformentioned factors the segment is expected to attain good growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to witness the fastest growth during the forecast period, owing to the rising opportunities, increasing healthcare expenditure, and the introduction of favorable government initiatives. Most global manufacturers of transcriptomic systems, platforms, equipment, and technologies are active in North America, especially in the U.S. For instance, in 2021, Rebus Biosystems launched its spatial transcriptomics analysis platform “spatial omics” system, designed to give researchers a closer look at the output of individual cells across tissue samples. Such product launches will positively influence the market in the upcoming period.
Due to the high transmission rate and lack of treatment of COVID-19, North American countries have suffered and are continuing to bear a significant burden on both their economies and healthcare systems. Owing to the shutting down of research and academic institutes, there has been a decline in the sales of reagents and consumables used for transcriptomics analysis. As per the annual report of 2020 by Nanostring Technologies Inc., the company witnessed a massive decline of 18% in its Consumables segment compared to 2019. According to the 2020 results published by 10X Genomics Inc., the company observed a decline of 23.0% compared to 2019. However, the situation is found to be improving gradually.
Competitive Landscape
The transcriptome market is moderately competitive with few of the major players holding the dominant position. Market leaders with more funds for research and a better distribution system have established their position in the market. Market players are engaged in introducing novel solutions with a competitive advantage to enhance their market position in the coming years. For instance, in February 2019, Caris Life Sciences launched its newest addition to its comprehensive genomic profiling offering, MI Transcriptome, which enables Whole Transcriptome Sequencing (WTS). MI Transcriptome uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patients' tumors and builds upon Caris' offering of the most comprehensive tumor profiling approach, which assesses DNA, RNA and proteins to ensure patients receive the right therapies. Some of the key players in the market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., GE Healthcare, Merck KGaA among others.
Reasons to Purchase this report:
This product will be delivered within 2 business days.
The COVID-19 has had a both positive as well as a negative impact on life science as well as the pharmaceutical industry globally. Certain market segments have been more severely affected due to the decrease in the demand for reagents, consumables, and instruments as well as due to supply chain disruptions and trade restrictions. In June 2020, NanoString Technologies, Inc. launched new solutions to study the immune response in COVID-19 disease research. The company launched the nCounter Host Response Gene Expression Panel and the COVID-19 Panel Plus spike-in to provide a comprehensive analysis of the viral infection and immune response. Thus, the current global pandemic has created considerable opportunities for the market players operating in the space.
Transcriptomics is the study of the entire set of RNA transcripts produced by the genome of any organism. Increase in advancements in the field of transcriptomics such as extensive use of RNA-sequencing and rise in application of transcriptomics, which includes drug discovery is expected to drive the growth of the transcriptomics market. In addition, rise in funding and grants by various private and government organizations have further stimulated the growth of the Transcriptomics Market.
Moreover, key market players are focused on expanding their transcriptomics footprints by entering into strategic partnerships and collaborations with other players. Moreover, the companies are undertaking strategies to expand their customer base across the globe. For instance, in February 2020, Dovetail Genomics announced the global availability of its Dovetail HiChIP and Micro-C Kits.
In Februry 2020, Caris Life Sciences launched of its newest addition to its comprehensive genomic profiling offering, MI Transcriptome, which enables Whole Transcriptome Sequencing (WTS). MI Transcriptome uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patients’ tumors and builds upon Caris’ offering of the most comprehensive tumor profiling approach, which assesses DNA, RNA and proteins to ensure patients receive the right therapies. Such product launches will work in the favour of the market growth.
However, certain drawbacks of RNA sequencing and lack of skilled professionals are expected to restrain the market growth.
Key Market Trends
Application of Transcriptomics in Diagnostics and Disease Profiling is expected to Grow in the forecast period
Transcriptomics has a variety of applications in diagnostics and disease analysis. Transcriptome analyses have been extensively used to understand the heterogeneity of tumors, classifying tumors into molecular subtypes and establishing signatures that predict response to therapy and patient outcomes. Massively-parallel single-cell RNA sequence analysis has emerged as a powerful method to understand the heterogeneity and to study cancer’s rare cell populations, through unsupervised sampling and modeling of transcriptional states in single cells.
The global spread of COVID-19 urgently demands a more comprehensive molecular understanding of the disease pathophysiology. And while an effective vaccine candidate is still elusive, therapeutic management of COVID-19 patients is pivotal in mitigating the clinical burden, as well as decreasing mortality rates. The research article published "Use of whole blood transcriptomes may improve COVID-19 diagnosis and treatment" in 2020, reported the first evidence for the use of whole blood transcriptomics to distinguish coronavirus disease (COVID-19) from other infections, and also to monitor and potentially predict disease outcomes. Thus, rising use of transcriptomics in the field of COVID-19 is likely have profiund impact on the market studied.
In recent years, transcriptomics has shifted from strictly research applications to diagnostics and disease applications. Transcriptomics are major tools for accelerating disease diagnostics processes. With the rapidly increasing global burden of chronic diseases such as cancer and diabetes, there is a need for advanced technologies for diseases and diagnostics. For instance, as per the report published by GLOBOCAN 2020, there were around 19.2 million new cases and 9.95 million deaths of cancer were reported across the globe. This rapidly increasing patient pool is likely to positively influencing segmental growth.
Various market players operating in the transcriptomics market are constantly focusing on developing and introducing novel instruments and techniques in the arena of diseases and diagnostics. For instance, in October 2019, Ambry Genetics (Ambry) launched the transcriptomic test namely +RNAinsight. This test enables clinicians for the first time ever to conduct both DNA and RNA genetic testing at the same time. Hence, owing to the afformentioned factors the segment is expected to attain good growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to witness the fastest growth during the forecast period, owing to the rising opportunities, increasing healthcare expenditure, and the introduction of favorable government initiatives. Most global manufacturers of transcriptomic systems, platforms, equipment, and technologies are active in North America, especially in the U.S. For instance, in 2021, Rebus Biosystems launched its spatial transcriptomics analysis platform “spatial omics” system, designed to give researchers a closer look at the output of individual cells across tissue samples. Such product launches will positively influence the market in the upcoming period.
Due to the high transmission rate and lack of treatment of COVID-19, North American countries have suffered and are continuing to bear a significant burden on both their economies and healthcare systems. Owing to the shutting down of research and academic institutes, there has been a decline in the sales of reagents and consumables used for transcriptomics analysis. As per the annual report of 2020 by Nanostring Technologies Inc., the company witnessed a massive decline of 18% in its Consumables segment compared to 2019. According to the 2020 results published by 10X Genomics Inc., the company observed a decline of 23.0% compared to 2019. However, the situation is found to be improving gradually.
Competitive Landscape
The transcriptome market is moderately competitive with few of the major players holding the dominant position. Market leaders with more funds for research and a better distribution system have established their position in the market. Market players are engaged in introducing novel solutions with a competitive advantage to enhance their market position in the coming years. For instance, in February 2019, Caris Life Sciences launched its newest addition to its comprehensive genomic profiling offering, MI Transcriptome, which enables Whole Transcriptome Sequencing (WTS). MI Transcriptome uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patients' tumors and builds upon Caris' offering of the most comprehensive tumor profiling approach, which assesses DNA, RNA and proteins to ensure patients receive the right therapies. Some of the key players in the market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., GE Healthcare, Merck KGaA among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 10x Genomics
- Agilent Technologies, Inc.
- BGI Genomics
- Bio-Rad Laboratories, Inc.
- Dovetail Genomics
- F. Hoffmann-La Roche AG
- Fluidigm Corporation
- GE Healthcare
- Illumina Inc.
- Merck KGaA
- Natera Inc.
- PerkinElmer, Inc.
- Promega Corporation
- Qiagen NV
- Thermo Fisher Scientific
Methodology
LOADING...
